|
|
Royalty Pharma Plc (NASDAQ: RPRX) |
|
Price: $58.9800
$0.37 
0.631%
|
| Day's High:
| $59.54999923706055
| Week Perf:
| -2.66 %
|
| Day's Low: |
$ 57.75 |
30 Day Perf: |
0.72 % |
| Volume (M): |
1,326,128 |
52 Wk High: |
$ 64.38 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$47.18 |
| Open: |
$58.66 |
52 Wk Low: |
$34.63 |
|
|
| Market Capitalization (Millions $) |
32,846 |
| Shares
Outstanding (Millions) |
557 |
| Employees |
100 |
| Revenues (TTM) (Millions $) |
2,536 |
| Net Income (TTM) (Millions $) |
1,350 |
| Cash Flow (TTM) (Millions $) |
-46 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Royalty Pharma Plc is a pharmaceutical company that specializes in acquiring and managing royalty interests in innovative biopharmaceutical products. Established in 1996, the company has since grown to become the largest buyer of biopharmaceutical royalties in the world.
As a business model, Royalty Pharma does not engage in the research, development, or commercialization of new drugs. Instead, the company acquires the rights to receive future royalties from the sale of existing therapies. In doing so, it provides a valuable source of financing for drug developers and manufacturers, while also generating revenue through the collection of these royalties.
The company's portfolio includes approximately 50 different products that are sold around the world. These products are primarily used in the treatment of cancer, immunological disorders, infectious diseases, and rare genetic disorders. Some of the notable products in the Royalty Pharma portfolio include the cancer drug Imbruvica, the HIV therapy Prezcobix, and the cystic fibrosis treatment Kalydeco.
Aside from acquiring and managing royalty interests, Royalty Pharma also invests in the development of new therapies. The company partners with pharmaceutical companies and academic institutions to fund research and development programs that may lead to new, innovative treatments. Thus, Royalty Pharma is a key contributor to the advancement of modern medicine.
Royalty Pharma is headquartered in New York City and has additional offices in London, Dublin, and Jersey City. The company went public in June 2020 and is currently listed on the NASDAQ Stock Exchange under the ticker symbol RPRX. With a market capitalization of over $30 billion, Royalty Pharma is considered one of the largest and most successful pharmaceutical companies in the world.
Company Address: 110 East 59th Street New York 10022 NY
Company Phone Number: 883-0200 Stock Exchange / Ticker: NASDAQ RPRX
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Management Announcement
Published Wed, Jan 29 2025 2:00 PM UTC
Royalty Pharma s Ambitious Financial Maneuvers: A Deep Dive into Recent Moves and Their Implications for Shareholder ValueIn a bold attempt to reshape its financial landscape and enhance shareholder value, Royalty Pharma plc (NASDAQ: RPRX) has announced several significant developments in the past few weeks. These moves follow a period of stock underperformance, raising ques...
|
| Dividend
Published Thu, Jan 9 2025 9:15 PM UTC
Royalty Pharma Boosts Investor Confidence with Dividend Increase Amid Strategic MovesBy Published January 10, 2025NEW YORK In a bid to solidify its commitment to enhancing shareholder value, Royalty Pharma plc (Nasdaq: RPRX) announced on January 9, 2025, a strategic dividend increase that signals confidence amidst the fluctuating market landscape. The company’s board of ...
|
| Merger and Acquisition
Published Fri, Jan 10 2025 12:15 PM UTC
Royalty Pharma s Bold Move: A Quest for Growth and Shareholder ValueIn an eye-catching announcement made on January 10, 2025, Royalty Pharma plc (NASDAQ: RPRX) revealed significant plans aimed at reshaping the company s future and boosting its value for investors. This comes in a context where the company has faced a challenging quarter, reflected in its stock declining by ...
|
| Contract
Published Thu, Nov 7 2024 12:10 PM UTC
: This article discusses the recent announcement by Royalty Pharma plc regarding its acquisition of a synthetic royalty on U.S. sales of Geron Corporation s RYTELO for $125 million. The financial implications of this acquisition are explored in the context of Royalty Pharma s overall performance in the second quarter of 2024, highlighting its return on investment (ROI) fig...
|
| Dividend
Published Fri, Oct 11 2024 12:15 PM UTC
Royalty Pharma Declares Fourth Quarter Dividend Amid Strategic Partnerships and Market FluctuationsNEW YORK, Oct. 11, 2024 Royalty Pharma plc (Nasdaq: RPRX) has announced a fourth-quarter dividend of $0.21 per Class A ordinary share, underscoring the company s commitment to shareholder returns even as it navigates a turbulent market landscape.The announcement comes in the ...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
1.87 $ |
| Revenues (TTM) |
4.55 $
|
| Cash Flow (TTM) |
- |
| Cash |
1.5 $
|
| Book Value |
17.57 $
|
| Dividend (TTM) |
0.92 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
25,359,980 |
| Net
Income per Employee (TTM) |
13,498,660 |
| Receivable Turnover Ratio (TTM) |
- |
| Inventory Turnover Ratio (TTM) |
- |
| Asset Turnover Ratio (TTM) |
0.32 |
|
|
| Per Share |
|
| Earnings (TTM) |
1.87 $
|
| Revenues (TTM) |
4.55 $ |
| Cash Flow (TTM) |
- |
| Cash |
1.5 $
|
| Book Value |
17.57 $ |
| Dividend (TTM) |
0.92 $ |
|
|
| |
| Financial Royalty Assets |
|
 182.9 % |
of total Revenue |
| Royalty Income, Other |
|
10.64 % |
of total Revenue |
| |
On January 10 2025 the Royalty Pharma Plc provided following guidance
nnRoyalty Pharma Plc Provides Business Update and Financial Guidance Ahead of J.P. Morgan Healthcare Conferencenn
nnNew York, January 10, 2025nn – Royalty Pharma Plc (Nasdaq: RPRX) has announced an update on its recent business performance, including notable achievements and its financial outlook for the fiscal year 2024 regarding Portfolio Receipts. The company’s founder and Chief Executive Officer, Pablo Legorreta, is set to address these developments during a webcast presentation scheduled for January 14, 2025, at 6:45 p.m. Eastern Time / 3:45 p.m. Pacific Time. This presentation will be a significant feature of the 43rd Annual J.P. Morgan Healthcare Conference.
While Royalty Pharma...
|
|
|
1.92% 